Cybin Completes $34.5 Million Overnight Marketed Offering
On August 3, 2021, Cybin Inc. (NEO: CYBN) (the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, completed an overnight marketed offering pursuant to a prospectus supplement to the Company’s short form base shelf prospectus dated July 5, 2021. In connection with the offering, the Company issued 10,147,600 common shares at a price of $3.40 per common share for aggregate gross proceeds of $34,501,840.
Cybin intends to use the net proceeds from the offering for general corporate and working capital purposes.
Aird & Berlis acted for Cybin with a team that included Sherri Altshuler, Marek Lorenc, Danny Kharazmi, Sean Green and Meredith McCann (Capital Markets/M&A) and Barbara Worndl (Tax).